Indivior Pharmaceuticals, Inc 6-K, filed Feb 27, 2025
Indivior Pharmaceuticals, Inc. (INDV)
6-K
2025-02-27
For: 2025-02-27
View Original
Added on
July 07, 2026
About this 6-K
Indivior Pharmaceuticals, Inc filed this 6-K on February 27, 2025.
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of February 2025
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Form
20-F ☒ Form 40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit No.
|
Description of Exhibit
|
|
99.1
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Indivior PLC
|
|
Date: February 27, 2025
|
/s/
Kathryn Hudson
|
|
|
Name:
Kathryn Hudson
|
|
|
Title:
Company Secretary
|
Exhibit
99.1
Indivior Announces Joseph Ciaffoni Appointed Chief Executive
Officer
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF
ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS
PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION
(WITHDRAWAL) ACT 2018)
Indivior PLC has appointed Joe Ciaffoni, currently an Independent
Non-Executive Director of the Company, as Chief Executive Officer.
The terms of his appointment are subject to, and effective upon,
the approval by shareholders of a new remuneration policy at the
Company's AGM in May 2025.
Mr. Ciaffoni, 53, was appointed as an Independent Non-Executive
Director to Indivior's Board in December 2024. He is a proven
public company CEO with more than 30 years of experience in
pharmaceuticals and biotech, working in both global and US
organizations. He has a strong track record of operational and
strategic success, working across diverse models and therapeutic
areas spanning specialty, rare disease, mass market and hospital.
He most recently served as President and CEO of Collegium
Pharmaceutical and has held senior roles as Endo International,
Biogen and Shionogi Inc.
By mutual agreement, Mark Crossley will be stepping down as Chief
Executive Officer and as a Board Director following a distinguished
tenure leading the Company. Mark will remain with Indivior to
support the transition, ensuring stability and continuity for the
business, and is expected to remain as CEO until at least the date
of the Company's AGM in May 2025.
David Wheadon, Chair of Indivior's Board of Directors,
said: "We are delighted to appoint
Joe as our next Chief Executive Officer. He is an accomplished
leader with a strong track record of delivering positive outcomes
for patients while generating shareholder value. He has a clear
mandate to fuel the next stage of Indivior's growth and deliver on
the Company's significant potential and we look forward to
supporting his success as CEO."
Joe Ciaffoni
said: "It is an
honor to be appointed as CEO of Indivior is a leader in the
addiction treatment space and its work has never been more
necessary. I look forward to working with the team to deliver on
the Company's potential and to drive Indivior's future growth for
the benefit of all our stakeholders".
Mark was appointed as CEO in June 2020. Under his stewardship, the
Company has strengthened its commitment to patients, expanded
access to treatment, and advanced its mission of pioneering
life-transforming treatments for substance use
disorders.
David Wheadon said: "On behalf of the Board of
Directors, I would like to thank Mark for his many contributions to
Indivior and wish him the best in his future endeavors. His
integrity and commitment to our patients and the people of Indivior
will leave a lasting impact."
Mark Crossley said: "It has been
a tremendous privilege to have worked at Indivior over the last
decade, the last five as CEO. I truly believe in our vision and
commitment to helping our patients and widening access to
treatment, a belief I know is shared by the many incredible
colleagues across the business. I am proud of the pivotal role
Indivior plays in combatting one of the great human crises of our
lifetime and I wish the business every success going
forward."
The person responsible for making this announcement is Kathryn
Hudson, Company Secretary.
For Further Information
|
Investor Enquiries
|
Jason Thompson
|
VP,
Investor Relations Indivior PLC
|
+1
804 402 7123
jason.thompson@indivior.com
|
|
|
Tim Owens
|
Director, Investor Relations Indivior PLC
|
+1
804 263 3978
timothy.owens@indivior.com
|
|
Media Enquiries
|
Jonathan Sibun
|
Teneo
U.S. Media Inquiries
|
+44
(0)20 7353 4200
Indivior@teneo.com
+1
804 594 0836
Indiviormediacontacts@indivior.com
|
About Indivior
Indivior is a global pharmaceutical company working to help change
patients' lives by developing medicines to treat substance use
disorders (SUD). Our vision is that all patients around the world
will have access to evidence-based treatment for the chronic
conditions and co-occurring disorders of SUD. Indivior is dedicated
to transforming SUD from a global human crisis to a recognized and
treated chronic disease. Building on its global portfolio of OUD
treatments, Indivior has a pipeline of product candidates designed
to
expand on its heritage in this category.
Headquartered in the United States in Richmond, VA, Indivior
employs over 1,000 individuals globally and its portfolio of
products is available in over 30 countries worldwide.
Visit www.indivior.com to learn more. Connect with
Indivior on LinkedIn by
visiting www.linkedin.com/company/indivior.